Kathleen Fenn, MD

Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.

Kearney M, Vanguri R, Wang Q, Fenn K, Guo H, Marks D, Hibshoosh H, Kalinsky K, Connolly E. Abstract P2-07-09: Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer. Cancer Research 2022, 82: p2-07-09-p2-07-09. DOI: 10.1158/1538-7445.sabcs21-p2-07-09.

Pan Q, Zeleke T, Chiuzan C, Onishi M, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, Califano A, Kalinsky K, Yu J, Silva J. Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat. Cancer Research 2021, 81: 645-645. DOI: 10.1158/1538-7445.am2021-645.

Fenn K, Singh V, Lee S, Cieremans D, Lassman A, Hershman D, Crew K, Accordino M, Trivedi M, Iwamoto F, Schultz R, Huynh L, Sales E, Fisher D, Mayer J, Kreisl T, Kalinsky K. Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF). Journal Of Clinical Oncology 2020, 38: 3567-3567. DOI: 10.1200/jco.2020.38.15_suppl.3567.

Fenn K, Marks D, Vanguri R, Boboila S, Guo H, Hibshoosh H, Kalinsky K, Connolly E. Abstract P6-10-25: Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer. Cancer Research 2020, 80: p6-10-25-p6-10-25. DOI: 10.1158/1538-7445.sabcs19-p6-10-25.

Kalinsky K, Chiuzan C, Onishi M, Trivedi M, Accordino M, Zeleke T, Pan Q, Kelly S, Honan E, Wu R, Fenn K, Crew K, Hershman D, Maurer M, Yu J, Silva J. Abstract P1-19-27: Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC). Cancer Research 2020, 80: p1-19-27-p1-19-27. DOI: 10.1158/1538-7445.sabcs19-p1-19-27.

Fenn K, Maurer M, Lee S, Crew K, Trivedi M, Accordino M, Hershman D, Kalinsky K. Abstract P6-18-35: A phase 1 study of erlotinib and metformin in advanced triple negative breast cancer. Cancer Research 2019, 79: p6-18-35-p6-18-35. DOI: 10.1158/1538-7445.sabcs18-p6-18-35.

Malhotra S, Huang K, Simeunovic K, Vinnakota R, Gavrancic T, Villanueva N, Dietz D, Fenn K, Beck K, Coker C, Park Y, Acharyya S. Survival in veterans with lung cancer: Cancer cachexia and the importance of weight. Journal Of Clinical Oncology 2015, 33: e20608-e20608. DOI: 10.1200/jco.2015.33.15_suppl.e20608.